Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/212832
Share/Export:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Title

Liver stiffness at the time of sustained virological response predicts the clinical outcome in HIV/HCV-coinfected patients with advanced fibrosis treated with direct-acting antivirals

AuthorsCorma-Gómez, Anaïs; Macias, Juan; Téllez, Francisco; Freyre-Carrillo, C.; Morano-Amado, Luis E.; Rivero-Juárez, Antonio; Ríos-Villegas, María José; Alados, Juan Carlos; Vera-Méndez, Francisco Jesús; Merchante, Nicolás; Palacios, Rosario; Granados, Rafael; Merino, Dolores; De Los Santos, Ignacio; Pineda, Juan A.
KeywordsHIV/HCV coinfection
Sustained
Virological
Response
Direct-acting antivirals
Cirrhosis
Hepatocellular carcinoma
Issue Date2020
PublisherOxford University Press
CitationClinical Infectious Diseases (2020)
Abstract[Background] Some people living with hepatitis C virus (HCV) with sustained virological response (SVR) develop hepatic complications. Liver stiffness (LS) predicts clinical outcome in people living with human immunodeficiency virus (HIV) with active HCV coinfection, but information after SVR is lacking. We aimed to analyze the predictive ability of LS at SVR for liver complications in people living with HIV/HCV with advanced fibrosis treated with direct-acting antivirals (DAA). [Methods] In sum, 640 people living with HIV/HCV fulfilling the following criteria were included: (i) Achieved SVR with DAA-including regimen; (ii) LS ≥ 9.5 kPa before therapy; and (iii) LS measurement available at SVR. The primary endpoint was the occurrence of a liver complication—hepatic decompensation or hepatocellular carcinoma (HCC)—or requiring liver transplant after SVR. [Results] During a median (Q1–Q3) follow-up of 31.6 (22.7–36.6) months, 19 (3%) patients reached the primary endpoint. In the multivariate analysis, variables (subhazard ratio [SHR] [95% confidence interval]) associated with developing clinical outcomes were: prior hepatic decompensations (3.42 [1.28–9.12]), pretreatment CPT class B or C (62.5 [3.08–1246.42]) and MELD scores (1.37 [1.03–1.82]), CPT class B or C at SVR (10.71 [1.32–87.01]), CD4 cell counts <200/µL at SVR time-point (4.42 [1.49–13.15]), FIB-4 index at SVR (1.39 [1.13–1.70]), and LS at SVR (1.05 [1.02–1.08] for 1 kPa increase). None of the 374 patients with LS <14kPa at SVR time-point developed a liver complication or required hepatic transplant. [Conclusions] LS at the time of SVR after DAA therapy predicts the clinical outcome of people living with HIV/HCV with advanced fibrosis. These results suggest that LS measurement may be helpful to select candidates to be withdrawn from surveillance programs.
DescriptionOn behalf of RIS-HEP13 and GEHEP 011 study groups. In Press.
Publisher version (URL)https://doi.org/10.1093/cid/ciz1140
URIhttp://hdl.handle.net/10261/212832
DOI10.1093/cid/ciz1140
Identifiersdoi: 10.1093/cid/ciz1140
e-issn: 1537-6591
issn: 1058-4838
Appears in Collections:(IBIS) Artículos

Files in This Item:
File Description SizeFormat
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work

Google ScholarTM

Check

Altmetric

Dimensions


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.